Podcasts about Moderna

A princesa Aiko é adorada, tratada como uma verdadeira estrela e seria a sucessora do trono do seu pai, o imperador Naruhito. Caso o país a deixasse. Oiça aqui o último episódio do podcast “O Mundo A Seus Pés” com Koichi Osamura, politólogo e investigador na Universidade de Viena. Filho de pai japonês e mãe brasileira, Osamura explica por que razão não é provável que esta legislação seja alterada pelo Parlamento, em grande parte por causa do Partido Liberal Democrático, de direita e no poder praticamente desde o desde o fim da Segunda Guerra Mundial.See omnystudio.com/listener for privacy information.

Un descubrimiento reciente ha sorprendido tanto a arqueólogos como a vulcanólogos: una ciudad moderna, completamente enterrada por una erupción volcánica, acaba de ser desenterrada. Edificios, calles y objetos cotidianos permanecen inquietantemente intactos bajo capas de ceniza y piedra. ¿Podría este ser el Pompeya moderno? ¿Qué causó esta catástrofe? En este video, exploramos la historia, los hallazgos científicos y las imágenes inquietantes de una ciudad perdida por el fuego y la ceniza, y lo que nos dice sobre el poder destructivo de los volcanes en la actualidad. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sabemos la responsabilidad que implica traer un hijo al mundo, o tal vez hacerse cargo de una mascota. Por eso las parejas modernas están optando por no tener responsabilidades y gastarse su dinero en viajes y placer. Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Lo stop al decreto legge sui medici di famiglia, le parole di Giorgia Meloni all'assemblea annuale di Confcommercio sugli sgravi al ceto medio, la situazione in Medio Oriente. Con Donatella Gianforma di Donna Moderna, abbiamo parlato delle vacanze sempre più brevi e la tendenza di passarla nelle case dei parenti. La direttrice generale di Scenari Immobiliari, Francesca Zirnstein, è intervenuta in diretta per parlarci dei dati della compravendita degli immobili, in continuo aumento. Spazio Generali. Con noi, in diretta, Marco Oddone, Chief Marketing & Distribution Officer di Generali Italia, per parlaci della convention di Generali Italia, con più di diecimila agenti di Generali e Cattolica. Si parlerà di risparmio, sanità e di previdenza. “Non chiudere gli occhi”, la rubrica radiofonica nata dalla collaborazione tra Autostrade per l'Italia e @RTL 102.5 , dedicata alla sicurezza stradale. Ospiti di questa puntata, Ambra Sabatini, atleta paralimpica, testimonial di Autostrade per l'Italia. Oggi cominciano i mondiali di calcio 2026. Il punto con il nostro Paolo Pacchioni. L'attualità, commentata dall'editorialista del giornale Repubblica, Maurizio Molinari. All'interno di Non Stop News, con Giusi Legrenzi, Lucrezia Bernardo, Enrico Galletti e Massimo Lo Nigro.

In 2011, Stéphane Bancel walked away from the security of leading a 6,000-person diagnostics company to join a startup of about 50 people, built on an idea most scientists had dismissed: that messenger RNA could become medicine. Almost everyone told him not to do it. He gave the bet roughly a five percent chance. Nine years later, that same bet helped the world face a pandemic in 63 days.Stéphane Bancel is the Chief Executive Officer of Moderna. Under his leadership the company designed a COVID-19 vaccine on a computer within days of the genetic sequence being posted, delivered the first dose to a human just 63 days later, and scaled from zero manufacturing to a billion doses in twelve months. Today Moderna is building personalized cancer vaccines and using AI to reinvent how medicines are discovered and made.This conversation sits right at the heart of what I believe about leadership. That the chief executive is really the chief energy officer. That the boldest decisions are rarely about appetite for risk, they are about the asymmetry between what you could give the world and what you could actually lose. Stéphane lives both, and he is refreshingly honest about the storms, the doubts and the mistakes along the way.In our conversation, we explore: → The five percent bet: how he weighed an enormous upside against a manageable downside, and why his wife was the only one who said yes → What sailing without GPS taught him about staying calm when the storm hits, and why a storm always passes → The 63-day sprint, and the Sunday phone call that saved the manufacturing of a billion doses → Why he slowed a trial down so it would be a vaccine for the world, not a vaccine for white people → The future he sees: personalized cancer vaccines, the human body mapped in silico, and why he calls chemotherapy tomorrow's barbaric history“I still believe that we have not invented yet our best drug.” Stéphane Bancel, CEO of ModernaIf you have ever faced a decision that everyone around you called too risky, this one is about how to think, and how to stay calm, when you choose to leap anyway.

En este episodio exploramos una pregunta que pocos se atreven a hacer, pero que podría cambiar la manera en que entendemos el éxito, el bienestar y el verdadero empoderamiento.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Esperamos que bendiga tu vida tanto como bendijo la nuestra. Iglesia Cristiana Palabras de Vida.

After ImCheck's inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen last year.In a session at the Kadans Oncology Summit, he talks about how the exit materialised and about the oncology space, including highlights from ASCO 2026, ADCs, in vivo CAR-T and checkpoint inhibitors. He also reveals some of the most shocking lessons he learned from his time at Imcheck.---Learn more about Kadans' Oncology Clusters, where oncology biotechs grow from start-up to global player: https://bit.ly/kadans-oncology---⭐️ ABOUT THE SPEAKERPierre has 30 years of experience in the biopharmaceutical industry, including 9 years at ImCheck and more than 3 years as EVP, Chief Strategy Officer at Theravectys. Prior to this, he also spent 10 years in senior roles in Sanofi and Baxter Healthcare.

"Las ciudades que se respetan a sí mismas no derriban los monumentos arquitectónicos", dice una experta ante la pérdida de edificios emblemáticos de la era soviética.

GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/wam USE Code WAM to save 25% plus free shipping! USE Code WAM50 for 50% off on select items like the #10 cans & MRE packs! Pledge here! Just a dollar a month can help keep us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 EXCLUSIVE replays of hour plus long live shows are available here at $5 a month or more! GET 10% OFF ON SHILAJIT FROM DR. KAUFMAN WHEN YOU USE CODE WAM10 HERE: https://medauthentica.com/discount/WAM10?redirect=/products/authentica-shilajit%3Fsca_ref=10867124.wrNV3jkYSaMg9 HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# Josh Sigurdson reports again on the massively increasing cancer rate epidemic as cases skyrocket. While Pam Bondi and Tulsi Gabbard's husband battle cancer, there are a lot of questions regarding where this massive increase is coming from. While doctors claim they are "baffled" by the across the board increases in cancer rates internationally, it's abundantly clear where much of this epidemic stems from. Still, years after the 2021 explosion, few in mainstream science are willing to acknowledge the obvious connections. Rates by 2050 are set to affect almost everyone in the US and UK. Past senate hearings have shown a massive coverup in origin and the origin is pretty clear to anyone paying attention. Pfizer and Moderna have both acknowledged their part following investigations, yet people still roll their eyes and laugh at the connections to the mass injection campaign. While pathologists and even major government figures come out pointing to major studies, there is very little media attention. Pfizer is coming in with their so-called "solution" claiming that "cancer is the new Covid." When they say this, they mean monetarily. Yes, they actually have boasted about this helping them grow revenue as they attempt to come out with an injection for cancer. We've reported time and time again on real world potential solutions. Perhaps it is time for people to take a second look at these potential solutions and the testimonies that back them. Stay tuned for more from WAM! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2026

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- Verdades incomodas de ser maestra Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Der weltgrößte Börsegang steht bevor. Rüdiger und Robert analysieren das Potenzial. Erwähnte Titel: Alphabet, Arista Networks, Moderna, voestalpine, GoPro, Victorias Secret, Essyjet, IBMDieser Podcast wird unterstützt von Raiffeisenfonds, einer Marke der Raiffeisen Kapitalanlage GmbH. Über Geld zu reden ist wichtig, um finanzielle Transparenz und Verständnis zu fördern. Es hilft, Missverständnisse und Konflikte zu vermeiden und gemeinsame finanzielle Ziele zu setzen. Offene Gespräche über Geld ermöglichen es, Wissen zu teilen und voneinander zu lernen, was zu besseren finanziellen Entscheidungen führt. Zudem kann es helfen, finanzielle Ängste abzubauen und Unterstützung bei finanziellen Herausforderungen zu finden. Geldgespräche sind der Schlüssel zu finanzieller Gesundheit und Sicherheit. Mehr auch unter raiffeisenfonds.at, Prospekte beziehungsweise Basisinformationsblätter auf www.rcm.at unter der Rubrik „Kurse und Dokumente.Alle Folgen finden Sie auch auf KURIER.at und kronehit.at.Weitere Podcasts finden Sie unter KURIER.at/podcasts Hosted on Acast. See acast.com/privacy for more information.

As health workers in the Democratic Republic of Congo (DRC) continue to battle an ongoing Ebola outbreak, scientists around the world are racing to develop a vaccine against the strain of the virus that's causing it.Two approved vaccines exist for Ebola, but they target the Zaire strain of the virus, not the Bundibugyo strain causing the 2026 outbreak, which has so far killed 61 people with 359 confirmed cases in the DRC and neighbouring Uganda.In this episode, we speak to two scientists at the Oxford Vaccine Group at the University of Oxford, Teresa Lambe and Rebecca Makinson, who are developing a vaccine candidate for Bundibugyo virus. On June 1, they were among three research groups to receive fast-track funding from the Coalition for Epidemic Preparedness Innovations, alongside Moderna and IAVI.This episode was written and produced by Gemma Ware, Katie Flood and Mend Mariwany. Mixing by Eleanor Brezzi and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation.

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Boletín de noticias 04/06/26: Una pareja de ancianos lucha por su vida tras un violento asalto a su domicilio en NSW. Israel y Líbano alcanzan un nuevo acuerdo de alto el fuego. Cuba suspende las transacciones con Visa y Mastercard.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics' Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso's clinical trial in China will hold up in a global population.Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China's Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We'll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

Un descubrimiento reciente ha sorprendido tanto a arqueólogos como a vulcanólogos: una ciudad moderna, completamente enterrada por una erupción volcánica, acaba de ser desenterrada. Edificios, calles y objetos cotidianos permanecen inquietantemente intactos bajo capas de ceniza y piedra. ¿Podría este ser el Pompeya moderno? ¿Qué causó esta catástrofe? En este video, exploramos la historia, los hallazgos científicos y las imágenes inquietantes de una ciudad perdida por el fuego y la ceniza, y lo que nos dice sobre el poder destructivo de los volcanes en la actualidad. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailIn this fast-paced episode of Neo News, Eli and Ben tackle the rapidly shifting landscape of vaccine regulation and economics in the US. They discuss recent political maneuvers surrounding the Vaccine Injury Compensation Program (VICP) and how expanding liability could quietly push manufacturers out of the market entirely. The hosts also examine the FDA's recent hesitation to review Moderna's new mRNA flu vaccine, highlighting how these administrative roadblocks threaten the financial viability of developing novel vaccines—including critical immunizations for pediatric and neonatal populations. Tune in for a sharp analysis of how top-down policy changes might reshape everyday clinical practice!----1) https://thehill.com/policy/healthcare/5689850-kennedy-dismisses-vaccine-advisors/2) https://www.washingtonpost.com/opinions/2026/01/15/rfk-jr-vaccines-autism-vicp/3) https://www.nytimes.com/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html4) https://www.nytimes.com/2026/02/16/health/rfk-vaccine-manufacturers.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

Em audiências, lideranças petistas e classe trabalhadora criticaram a exaustiva jornada de trabalho de apenas uma folga por semana que reduz o tempo e a disposição para estudar e melhorar de vida. Manobras da direita tentam inviabilizar a medida aprovada por cerca de 80% da população.  Sonoras:

Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines, Lilly scooped up preclinical biotech Engage Bio for $202 million and teamed up with AI company Collaborative Drug Discovery for its life sciences data management solutions.These deals and Lilly's skyrocketing revenue pushed the Indianapolis-based company to the top of IDEA Pharma's list of best inventors and innovators.Lilly also continues to make headlines for its impressive data readouts, especially in the weight-loss space that it now reigns supreme. Last week, Lilly announced that next-gen asset retatrutide led to weight loss of 70 pounds, or 28.3% at 80 weeks, setting a new benchmark for the space.Moderna also made news this week with a surprising uptick in its share price that analysts are attributing to the so-called “fear trade” that is rising amid reports of a cluster of cases of hantavirus. Moderna also announced that its mRNA flu shot—initially turned away from the FDA but later accepted for review—will be discussed at an advisory committee on June 18.The annual conference of the American Society of Clinical Oncology starts on Friday in Chicago, where all eyes will be on Revolution Medicines' investigational pancreatic cancer pill and Akeso's Phase 3 trial HARMONi-6 for its Summit Therapeutics-partnered PD-1/VEGF bispecific ivonescimab.Finally, sign up for BioPharma Executive to receive this week's special edition breaking down executive compensation packages across the biggest pharmas.

The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries.  On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/wam USE Code WAM to save 25% plus free shipping! Pledge here! Just a dollar a month can help keep us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 EXCLUSIVE replays of hour plus long live shows are available here at $5 a month or more! GET 10% OFF ON SHILAJIT FROM DR. KAUFMAN WHEN YOU USE CODE WAM10 HERE: https://medauthentica.com/discount/WAM10?redirect=/products/authentica-shilajit%3Fsca_ref=10867124.wrNV3jkYSaMg9 GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! Josh Sigurdson reports on the ongoing efforts to renew pandemic fears as Bill Gates' GAVI gets further funding for a future "health threat" with $3.35 billion allocated. Simultaneously, Tedros of The World Health Organization announced that they have just completed yet another Event 201 style pandemic simulation. This happens as further fear is pushed by both the mainstream media and mainstream alternative media regarding Hantavirus. While many believe that this came out of nowhere, we've been reporting on it for a decade. Bill Gates claimed it was one of the top 11 potential candidates for a new pandemic back in 2022. Hantavirus was also studied for weaponization by the Pentagon in 2025 with work done on "aerosolizing" the contagion. Though it's doubtful this will happen. It is far more likely the fear alone will be the main contagion. It is however possible that the public could be poisoned in some way as a pretext to further future restrictions. Moves have already been made to roll out a ration based digital ID system in the face of a new "pandemic." Moderna was working with Korea University as far back as 2024 on an mRNA injection for Hantavirus. Interestingly, Moderna stock has skyrocketed following the announcement of the Hantavirus "outbreak" from the MV Hondius boat. Simultaneously, the government is pushing Measles injections. RFK Jr who was confirmed by a pharma funded house continues to push for tracking devices called wearables. President Trump has said he's interested in an "Operation Warpspeed 2.0." The FDA is looking to allow the "yoga mat" chemical in the food supply. The EPA apparently got a thank you letter from Bayer/Monsanto for allowing the cancer warning for glyphosate to be removed under this administration. So much for MAHA. Stay tuned for more from WAM! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2026

We mark National Mental Health Awareness Month on this episode by tapping the expertise of Dr. Steve Strakowski, an internationally recognized expert in bipolar disorder, who has spent decades studying the neurobiology and treatment of mood conditions while pushing just as hard on the structural barriers that keep effective treatments out of reach for more than half the people who need them. In this conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Strakowski explains why access, not science, is now the biggest obstacle to improving mental health outcomes. He also addresses the heavy toll society pays for underfunding mental health prevention and treatment programs. “The money is spent eventually, but in the most expensive places like emergency rooms and prisons, and there is the human cost of suffering and suicides." This important discussion also covers: The persistent problem of Black patients presenting with mania being misdiagnosed with schizophrenia;  Why he describes bipolar disorder as a reward-processing illness;  The emerging therapies he finds encouraging. Mentioned in this episode:Indiana University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The media is working overtime to manufacture the next viral panic, and pharma companies are making big money from the fear campaign. After confirming they were already working on a Hantavirus mRNA vaccine before the cruise ship outbreak – and also developing mRNA vax for ebola – Moderna's stock jumped 20%. What an odd coincidence… Diagnostic pathologist Dr. Clare Craig joins Dr. Drew to expose the suspicious timing behind the latest virus hysteria and what the pharmaceutical industry might be planning next – monkeypox, ebola, bird flu, or worse. Eric Bolling breaks down the economic warning signs flashing across the country as diesel prices near all-time highs. CA Lt. Gov. candidate Gloria Romero (running with Steve Hilton) exposes a new plot by California Democrats to repeal the “Top 2” primary system and change the rules of the election to maintain power. Dr. Clare Craig, BM BCh FRCPath, is a Diagnostic Pathologist and author of “Expired: Covid the Untold Story.” She practiced in the NHS for 15 years and became a Fellow of the Royal College of Pathologists. She was the day-to-day pathology lead for the cancer arm of the 100,000 Genomes Project and led R&D at Genomics England. She is Co-Chair of the Health Advisory and Recovery Team (HART Group). Follow at https://x.com/ClareCraigPath Eric Bolling is a TV personality, political commentator, and author. He is the host of TheEDGE and a former co-host of Fox News' The Five. A former commodities trader at the New York Mercantile Exchange specializing in crude oil, gold, and agricultural commodities, he also served on the NYMEX Board of Directors. He is a 2-time NYT bestselling author. Follow at https://x.com/ericbolling Gloria Romero is a candidate for California Lieutenant Governor, running alongside Steve Hilton. A former California State Senate Majority Leader, she was elected to the State Assembly in 1998 and the Senate in 2001. She left the Democratic Party in September 2024 and joined the Republican Party. She is also a professor, educator, and businesswoman. Learn more at https://gloriaromero.com 「 SUPPORT OUR SPONSORS 」 • COVEPURE – Do you know what's in your tap water? Get $250 off your purifier at https://covepure.com/DREW ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

The World Health Organization said 11 hantavirus cases were linked to a cruise ship, including three deaths. However, they also say only 8 of 11 were confirmed cases, and only then by assumptions derived from tests. The three deaths were not caused by the hantavirus. From Johns Hopkins to the CDC, the Hantavirus is described as one of many, with the Andes version being the only one that may be able to spread to humans in rare circumstances. Not only is this likewise unconfirmed, but in the worst case scenario the symptoms are the flu. Of those people on the cruise, the first couple who died were not classified as hanta-cases, and a third sick person had pneumonia which the WHO claims is now caused by Hanta. Meanwhile, there is a federal investigation over a coverup of COVID-19 origins which leads to reinforce the viral contagion narrative. The ship's name Hondius means "dog" and Hanta means "deceive". *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.

En El Ojo Crítico viajamos hasta la historia del Lyceum Club Femenino de la mano de la escritora Eva Cosculluela, autora de "El club de las modernas", una novela inspirada en aquellas pioneras que transformaron la vida cultural e intelectual de Madrid.En nuestra sección de ciencia, Xaviera Torres nos habla de los patos y de su inesperada relación con la literatura.La lírica llega de la mano de Enrique Mejías, que nos acerca al universo de La Cenicienta.Y Conxita Casanovas nos presenta la actualidad del Festival de Cine de Cannes.Escuchar audio

In this episode of Bowel Sounds, hosts Dr. Temara Hajjat and Dr. Peter Lu talk to Dr. Maureen Leonard, a pediatric gastroenterologist and Associate Professor at Massachusetts General Hospital. Dr. Leonard discusses the latest research on early life factors that can increase celiac disease risk for susceptible children, including potentially modifiable risk factors. Dr. Leonard's disclosures include:  Consultant for Takeda, Chugai, Anokion, Sonoma, and Interlude Biopharma and research support from Takeda, Pfizer, Regeneron, Moderna, and Mead Johnson Nutrition.Learning objectivesUnderstand early life determinants for celiac diseaseUnderstand environmental influences on developing celiac diseaseSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

As reflexões de Carl von Clausewitz exerceram enorme influência sobre o pensamento militar moderno e continuam presentes nos debates sobre guerra, estratégia e política. Escrevendo em meio às transformações provocadas pelas Guerras Napoleônicas, Clausewitz buscou compreender a natureza dos conflitos armados para além das batalhas em si, formulando conceitos que marcaram profundamente os estudos estratégicos posteriores. Em sua obra mais conhecida, Da Guerra, discutiu temas como a relação entre guerra e política, a fricção, o papel do acaso, a importância da moral das tropas e os limites do planejamento racional em cenários de combate. Seus escritos atravessaram os séculos XIX e XX influenciando militares, governantes e teóricos de diferentes correntes, ao mesmo tempo em que suscitaram interpretações variadas e debates sobre a aplicabilidade de suas ideias em guerras contemporâneas. Convidamos Delmo Arguelhes para analisar os principais conceitos desenvolvidos por Clausewitz, o contexto intelectual e militar em que suas obras foram produzidas e a permanência de seu pensamento nos debates sobre estratégia, política e teoria da guerra.Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iclesrodrigues⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PIX: leituraobrigahistoria@gmail.comAdquira o curso História: da pesquisa à escrita por apenas R$ 49,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso A Operação Historiográfica para Michel de Certeau por apenas R$ 24,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso O ofício do historiador para Marc Bloch por apenas R$ 29,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Colabore com nosso trabalho em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/obrigahistoria⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Versatilidade é com a INSIDER! Meu cupom HISTORIAFM dá 10% de desconto pra cliente recorrente e, até 25/05, dá 30% pra cliente novo! Acesse o site pelo link ⁠⁠⁠https://creators.insiderstore.com.br/HISTORIAFM⁠⁠⁠ e aproveite! #insiderstore

Una cubana en Miami se volvió viral tras lanzar una fuerte crítica contra las mujeres que —según ella— prefieren “chapear” antes que estudiar, trabajar y superarse por cuenta propia. Hoy abrimos el debate:¿Está mal buscar estabilidad económica en una relación?¿La independencia económica hace más saludables las parejas?¿Qué buscan realmente las mujeres hoy en día: amor, seguridad, apoyo… o todo junto? Un tema que tiene a las redes divididas y que seguramente también va a dividir opiniones al aireSee omnystudio.com/listener for privacy information.

Una cubana en Miami se volvió viral tras lanzar una fuerte crítica contra las mujeres que —según ella— prefieren “chapear” antes que estudiar, trabajar y superarse por cuenta propia. Hoy abrimos el debate:¿Está mal buscar estabilidad económica en una relación?¿La independencia económica hace más saludables las parejas?¿Qué buscan realmente las mujeres hoy en día: amor, seguridad, apoyo… o todo junto? Un tema que tiene a las redes divididas y que seguramente también va a dividir opiniones al aire.See omnystudio.com/listener for privacy information.

A Dutch couple goes "bird watching" at a landfill in Argentina. Days later, they board a cruise ship — and a Hantavirus outbreak that hadn't surfaced in years suddenly spreads across the passengers. Now Americans from that ship are quarantined in landlocked Nebraska, Moderna's stock has jumped 7.5% on a Hantavirus vaccine they were already developing, and the WHO wants $300 million back from the United States. Does any of this actually add up? Lance Wallnau breaks down the Hantavirus story the mainstream headlines won't touch — what's real, what's suspicious, and what every Christian needs to know before the next pandemic playbook gets rolled out. Bird watching at a landfill? Seriously?   In this episode:   The Argentina landfill detail that government investigators will only speak about anonymously Why Moderna's stock jumped 7.5% on a Hantavirus vaccine BEFORE the outbreak hit headlines The Wuhan wet-market parallel hiding inside the Patagonia origin story Why the WHO wants $300 million back from the U.S. — and why Trump is saying no What Dr. Peter McCullough is recommending Americans keep on hand right now The prophetic prayer over the outbreak — and why Lance believes this one dissipates A Dr. Ben Carson exclusive on the 1963 communist memo that predicted today's headlines America's 250th anniversary, the rededication on the 17th, and why young men are returning to faith in droves   This is the briefing the WHO doesn't want you watching — and the one every believer needs before the next news cycle hits.   Podcast Episode 2118: The Hantavirus 'Bird Watching' Story Nobody Actually Believes | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast  

"When the workforce does not align with the population, your system is misaligned by design." That candid observation comes from Tina Loarte-Rodríguez, DP, RN who has spent much of her two decade career in patient safety, risk management, and systems leadership as the only Latina in the room, which she sees as a signal of a systemic failure that demands structural solutions. As we mark National Nurses Month, Dr. Loarte-Rodríguez joins Raise the Line from Elsevier  host Lindsey Smith to explain why a culturally congruent workforce has important implications for access, trust and quality of care. This wide-ranging discussion also covers: What Dr. Loarte-Rodriguez means by "narrative infrastructure" and how a book series born during COVID is now shaping workforce conversations nationwide;   The case for making mentorship a core institutional system;   Why nursing burnout is not about a lack of resiliency.  Mentioned in this episode: Latinas in NursingThe Connecticut Center for Nursing Workforce If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Table of Contents: Genetic RNA “vaccines” are now being used in livestock across the U.S., Canada, Chile, Mexico, and the Philippines. Merck’s gene-based shots (SEQUIVITY) have been injected into MILLIONS of pigs across the globe since 2012 — and almost NO ONE knows! Moderna’s new FDA approved COVID injection mNEXSPIKE literally means VIOLENT DEATH in Latin–FDA approval despite ZERO placebo tests & SERIOUS adverse events of MYOCARDITIS & CANCER–“ALL COVID Vaccines should be PULLED from the market IMMEDIATELY.”~Dr Jeff Barke, MD THREE U.S. states have introduced legislation designating COVID-19 mRNA injections as BIOLOGICAL WEAPONS OF MASS DESTRUCTION Scott Johnson's 6 Part Teaching: Pharmakeia: Sorcery, Pharmaceuticals & the Roots of Modern Day Drug-Parts 1-6–September 21, 2008 Is There A 700% Food Price Increase Coming? ‘Megadrought Is HERE’: We Just Experienced the DRIEST First Three Months of a Year in US History “No Quick Fixes”: Prepare for Energy Rationing, Mandatory Water Restrictions, Higher Beef Prices Farmers are sounding the alarm and few are listening–American farmer, Julius Ray Tucker, just tested his soil & found 5X more aluminum than last year–His GMO seeds grow perfectly, but his heirloom crops are dying! — Meanwhile, Bill Gates is pushing GMO seeds engineered to thrive in aluminum-rich soil and geoengineering delivering that aluminum from our skies! Trump's Federal government using clever trick to force AI data centers on unsuspecting local communities–Trump executive order being used to override public opposition and local ordinances that forbid construction of massive AI data-collection centers that will power the coming 24/7 surveillance state! The LARGEST “hyperscale” data center in the world is being proposed in Box Elder County, Utah. It’s approx. 40,000 acres/62 square miles, backed by Canadian millionaire Kevin O'Leary. Fast-tracked by Utah's Military Installation Development Authority, backed by Gov. Spencer Cox, with the public locked out of the decision process. Utah, say hello to a 50% increase in CO₂ emissions, polluted water, and 24/7 noise and light pollution. Foreclosures Sweep Across America! Hundreds Of Thousands Of Families Have and Will Lose Their Homes Texas Governor Hands State Over To India Socialist Muslim Devil New York City Mayor Mamdani LEGALIZES Shoplifting… Wiping 8,400 Businesses OFF THE MAP Mayor Mamdani LEGALIZES Squatting… as NYC’s Largest Landlord ABANDONS 6,000 Apartments PDF: Emergency Freedom Alerts 5-11-26 Click Here To Play The Part 2 Audio Source

Joyce talks about:Virginia Rep. Jen Kiggans called to resign after agreeing with "Cotton picking hands," comment said about Minority Leader Hakeem Jeffries.CNN reports on details of sexual violence during the October 7th massacre. FDA Administrator Dr. Marty Makary stepping down after 13 months. Rumors say he clashed over rushes to get vaccines and vaping approvals. AG Todd Blanche warns anyone who may leak government secrets will face prosecution. Inflation on the rise.Politics and political games on both sides. Moderna flu trials risk vs benefit. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tras la evacuación del crucero MV Hondius, donde surgió un brote de hantavirus, los países redoblan esfuerzos para evitar nuevos contagios. De momento no existe ningún tratamiento ni vacuna, a pesar de algunos hallazgos prometedores de investigadores de Chile, uno de los países donde los roedores son portadores del hantavirus. Fue en los años 1950 cuando se detectó por primera vez un caso de hantavirus, en un contingente de soldados coreanos. Posteriormente se identificaron otros casos en los años 90 y 2000 en el continente americano. De momento, la cepa denominada Andes, presente en Chile y Argentina, donde los ratones colilargo transmiten el hantavirus, es la única del continente que se transmite de humano a humano y resulta mortal en alrededor del 40% de los casos. Fue precisamente esta cepa la que fue detectada en los pacientes afectados por el brote de hantavirus en el crucero MV Hondius que salió de Patagonia el 1° de abril. Aunque de momento no existe ninguna cura ni vacuna disponible, desde la Universidad Austral de Chile, el inmunólogo Alejandro Rojas utilizó anticuerpos de alpacas, unos camélidos andinos, para elaborar una terapia prometedora contra esta cepa de hantavirus. “Se trata de fragmentos de anticuerpos de alpacas que se logran unir a los virus de forma que los anticuerpos humanos no son capaces”, cuenta Rojas, entrevistado por RFI. El investigador constató que “los anticuerpos de alpacas son extremadamente efectivos en neutralizar infecciones virales”. Otra investigadora, María Inés Barria, investigó por su parte una posible vacuna contra el hantavirus suramericano. Sin embargo, ni esta doctora científica chilena ni Alejandro Rojas han podido llevar sus investigaciones a la etapa farmacéutica. “Siempre ha sido un problema en Suramérica. A nosotros, todos los años se nos mueren entre 10 y 20 personas por hantavirus en Chile, de los cuales algunos son niños”, recuerda Rojas. Sin embargo, “si bien hemos probado con el virus real que estos anticuerpos son capaces de bloquear el virus, nunca hemos tenido la posibilidad de llevarlo a gran escala”, se lamenta el inmunólogo. Rojas espera ahora que la atención internacional hacia el foco de infección del MV Hondius aliente a las grandes farmacéuticas de los países del norte global a desarrollar vacunas y tratamientos contra el hantavirus. “Ahora que hemos visto que el hantavirus puede salir de Suramérica, que puede causar pérdidas de vidas humanas y costos, quizá finalmente vamos a poder reunir a las organizaciones que puedan aportar en el desarrollo de esta terapia para que en Chile y en Argentina – lugar endémico donde habita el ratón colilargo – nunca más tengamos muertos de hantavirus”. En medio de la atención mediática causada por el brote en el crucero MV Hondius, el laboratorio estadounidense Moderna anunció investigaciones preliminares para desarrollar una vacuna contra el hantavirus.

Propaganda-Palooza: Hantavirus Warm-Up, UFO Thumb Drives, and a Robot Monk Walks Into a Temple McShane and Fitz open Propaganda-Palooza,” by ripping into overlapping narratives: a sudden hantavirus cruise-ship outbreak (plus norovirus headlines), WHO messaging, and renewed “pandemic prep” vibes they refuse to comply with again. The guys argue the fear cycle is timed, point to Moderna vaccine talk, play a 2017 Fauci clip about a “surprise outbreak,” and compare the rollout to an X-Files scene about hantavirus and emergency powers. They also cover a pastor claim that clergy were briefed to prepare congregations for alien disclosure, followed by Fox's Peter Doocey teasing AARO “UFO disclosure” files on a thumb drive, which they frame as distraction. Along the way: exploding beers, barrel-aged stout and barley wine reviews, a satire “SPCS” clip, climate narrative mockery, a discussion on dreaming and brain adaptation, a farm report, and outrage at a South Korean robot monk. We were balls deep this week and we think you're going to like every bit of it.  Download or stream usBecome a supporter of this podcast: https://www.spreaker.com/podcast/razor-wire-news--5683729/support.www.razorwirenews.com

Barbara from Yonkers, NY, shared that she's heard Moderna is supposedly working on a new vaccine for the Hantavirus. Dr. Bob called in, voicing concerns about Republican candidate Bruce Blakeman's campaign style.

Barbara from Yonkers, NY, shared that she's heard Moderna is supposedly working on a new vaccine for the Hantavirus. Dr. Bob called in, voicing concerns about Republican candidate Bruce Blakeman's campaign style.See omnystudio.com/listener for privacy information.

Las madres se donan por completo a sus hijos. El amor de una madre es un amor que se ofrece por el bien de sus hijos, es una capacidad de olvidarse de sí por ver bien a sus hijos, es el amor como una oblación para los hijos con paciencia y fortaleza. El programa del día de hoy, es para brindar un homenaje a nuestras madres. ¡No te pierdas el programa del día de hoy con Lupita Venegas, sólo aquí en Enamórate!

On this, our 325th Evolutionary Lens livestream, we discuss Hanta virus and drought. First: what is the natural history of Hantavirus, do any Hantaviruses transmit directly from human to human, and what is going on with the M.V. Hondius, the cruise ship on which Hantavirus has made a stand? Given its mechanisms of action, Ivermectin is likely to treat Hantavirus (a negative sense single-stranded RNA virus), but the WHO dismisses the possibility. Moderna is working on a Hantavirus vaccine, even though the Number Needed to Treat is sky high. What is going on? Then: in Washington state, we're experiencing a very wet drought. The Department of Ecology has declared a drought (again), and the snow pack is low, but all other indicators—from rivers to reservoirs to soil moisture—are excellent. Cliff Mass, atmospheric scientist, puts the evidence in one place and calls bull on the drought diagnosis.*****Our sponsors:Xlear: Xylitol nasal spray that acts as prophylaxis against respiratory illnesses by reducing the stickiness of bacteria and viruses. Find Xlear online, or at your local pharmacy, grocery store, or natural products store.Fresh Pressed Olive Oil Club: Freshly harvested and delicious. Go to http://www.GetFreshDarkHorse.com to get a bottle of the best olive oil you've ever had for $1 shipping.CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Hantavirus and the elders: https://asm.org/articles/2024/october/indigenous-knowledge-solved-mysterious-outbreakToledo et al 2022. Evidence for human-to-human transmission of hantavirus: a systematic review. The Journal of infectious diseases, 226(8): 1362-1371: https://academic.oup.com/jid/article/226/8/1362/6369311Zaidi & Dehgani-Mobaraki 2022. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. The Journal of antibiotics, 75(2): 60-71: https://www.nature.com/articles/s41429-021-00491-6The WHO on the recent outbreak: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON599Cliff Mass – There is no drought emergency: https://cliffmass.blogspot.com/2026/05/the-is-no-drought-emergency-in.htmlStatewide drought declared in WA: https://ecology.wa.gov/about-us/who-we-are/news/2026/april-8-statewide-drought-declared-due-to-dismal-snowpackSupport the show

RFK Jr.'s push to reduce antidepressant dependence is drawing fire from MSNBC and Reuters, and Jordan and Nate break down why. With 1 in 6 American adults on SSRIs and the global market generating $20 billion per year, the push for deprescribing pathways backed by a new CMS billing code is a genuine disruption to pharma revenue. RFK shares a personal account of a family member's SSRI withdrawal he describes as harder than heroin detox. The show then dismantles the hantavirus media cycle: 5 cases on a cruise ship, Moderna already codeveloping a vaccine, and Robert Malone reminding everyone that a lightning strike is statistically more likely. FDA Commissioner Makary's admission that the FDA deliberately misled the public on dietary fat for nearly two decades gets its moment, followed by a DOJ investigation into the Big Four meatpackers for antitrust violations and foreign ownership concerns. The episode closes with a discussion on statin overuse, CoQ10 depletion, thyroid health, iodine sources, and the structural problem of corporate consolidation across farming and food supply chains.